This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chamberlain, M. C. Search for Related Content PubMed PubMed Citation Articles by Chamberlain, M. C. Social Bookmarking                            What's this?

Neoplastic Meningitis

From the Department of Interdisciplinary Oncology, University of S Florida, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

Address reprint requests to Marc C. Chamberlain, MD, Professor, Neurology and Neurosurgery, Department of Neuro-Oncology, University of S Florida, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Dr, Suite 3136, Tampa, FL 33612; e-mail: chambemc{at}moffitt.usf.edu

Neoplastic meningitis (NM) is a common problem in neuro-oncology occurring in approximately 5% of all patients with cancer, and is the third most common site of CNS metastases. NM is a disease affecting the entire neuraxis, and therefore clinical manifestations are pleomorphic affecting the spine, cranial nerves, and cerebral hemispheres. Because of craniospinal disease involvement, staging and treatment need to encompass all CSF compartments. Treatment of NM utilizes involved-field radiotherapy of bulky or symptomatic disease sites and intra-CSF drug therapy. The inclusion of concomitant systemic therapy may benefit patients with NM and may obviate the need for intra-CSF chemotherapy. At present, intra-CSF drug therapy is confined to three chemotherapeutic agents (ie, methotrexate, cytarabine, and thiotepa) administered by a variety of schedules either by intralumbar or intraventricular drug delivery. Although treatment of NM is palliative with an expected median patient survival of 2 to 6 months, it often affords stabilization and protection from further neurologic deterioration in patients with NM.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Y. Lv, N.-K. V. Cheung, and B. M. Fu A Pharmacokinetic Model for Radioimmunotherapy Delivered Through Cerebrospinal Fluid for the Treatment of Leptomeningeal Metastases J. Nucl. Med., August 1, 2009; 50(8): 1324 - 1331. [Abstract] [Full Text] [PDF]

				T. KUBO, N. TAKIGAWA, K. KIURA, A. NISHIDA, N. OCHI, H. KASHIHARA, S. UMEMURA, A. HISAMOTO, and M. TANIMOTO Efficacy of a Lumbo-peritoneal Shunt for Meningeal Carcinomatosis Refractory to Gefitinib Treatment Anticancer Res, July 1, 2009; 29(7): 2759 - 2760. [Abstract] [Full Text] [PDF]

				D. C. Gammon, M. S. Bhatt, L. Tran, A. Van Horn, M. Benvenuti, and M. J. Glantz Intrathecal topotecan in adult patients with neoplastic meningitis. Am. J. Health Syst. Pharm., November 1, 2006; 63(21): 2083 - 2086. [Abstract] [Full Text] [PDF]